Regular review: Managing testicular cancer
- 30 June 2001
- Vol. 322 (7302), 1583-1588
- https://doi.org/10.1136/bmj.322.7302.1583
Abstract
Germ cell tumours of the testis are the commonest malignancy in men aged 20–40 years. Considerable therapeutic improvements in management—based on the cancer's responsiveness to chemotherapy that contains platinum — mean that over 95% of these patients can now expect to be cured. #### Summary points Testicular cancer is the most common cancer in younger men The incidence has been increasing by 15-20% in successive five year periods Clinical trials organised by the UK's Medical Research Council and other international groups have defined modern clinical practice Cure rates of >95% can be achieved Advanced and recurrent cancers should be treated by multidisciplinary teams in specialist centres Much of the clinical management discussed in this review is based on the guidelines of the UK's Clinical Oncology Information Network, which were developed with the Scottish Intercollegiate Guidelines Network.1 These were based on a systematic review of clinical data including prospective phase III randomised trials performed internationally. The sections that discuss causes, follow up, and future developments reflect our research interests and personal experience. ### Testicular germ cell tumours Testicular germ cell tumours are uncommon cancers; they account for around 1% of all cancers in males. About 1400 new cases are diagnosed in the United Kingdom each year. Germ cell tumours have a unique epidemiological profile for a solid tumour. Their peak incidence occurs among men aged 25–35 years, and there is a distinctive geographical and racial variation. The highest incidence is among white men in northern Europe. These factors suggest that both genetic and environmental factors are important in the development of testicular germ cell tumours. The age distribution at onset suggests that an initiating event occurs prenatally and that the tumour develops from adolescence. The overall incidence of testicular germ cell tumours has been steadily rising throughout the 20th century, with an increase of 15-20% being seen in …This publication has 27 references indexed in Scilit:
- Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adultsBritish Journal of Cancer, 2001
- Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment aloneRadiotherapy and Oncology, 2001
- Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research CouncilJournal of Clinical Oncology, 2001
- A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminomaBritish Journal of Cancer, 2000
- Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapseBritish Journal of Cancer, 2000
- Localization to Xq27 of a susceptibility gene for testicular germ-cell tumoursNature Genetics, 2000
- Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party.Journal of Clinical Oncology, 1992
- Public awareness of testicular cancer and the value of self examination.BMJ, 1986
- The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP)British Journal of Cancer, 1983
- Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular CancerAnnals of Internal Medicine, 1977